Adaptive Biotechnologies (ADPT) Total Debt (2022 - 2026)

Adaptive Biotechnologies has disclosed Total Debt across 5 years of filings, most recently posting $130.6 million for Q1 2026.

• Total Debt for Q1 2026 came in at $130.6 million, down 2.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $130.6 million (down 2.25% YoY), and the FY2025 annual result was $131.2 million, down 1.55% from the prior year.
• Total Debt came in at $130.6 million for Q1 2026 at Adaptive Biotechnologies, roughly flat from $131.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $133.6 million in Q2 2025 to a low of $125.4 million in Q4 2022.
• The 5-year median for Total Debt is $131.7 million (2024), against an average of $131.4 million.
• Across the five-year window, Total Debt grew 4.23% in 2023 and dropped 2.25% in 2026, its largest moves.
• Adaptive Biotechnologies' Total Debt stood at $125.4 million in 2022, then climbed by 4.23% to $130.7 million in 2023, then increased by 2.0% to $133.3 million in 2024, then decreased by 1.55% to $131.2 million in 2025, then fell by 0.5% to $130.6 million in 2026.
• The last three Total Debt figures came in at $130.6 million (Q1 2026), $131.2 million (Q4 2025), and $131.8 million (Q3 2025), per Business Quant data.